Entero Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure

GridAI Technologies Corp.

Nasdaq notified Entero on Sept 6, 2024 that common stock failed minimum $1.00 bid price for 30 consecutive business days.
Company has until March 5, 2025 to regain compliance by closing at $1.00 for 10 consecutive business days.
If not compliant, Nasdaq may grant second 180-day period if other listing standards met; otherwise delisting possible.
Company intends to monitor bid price and seek compliance; no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.